CRYO-CELL INTL DL-,01

The NYSE American has accepted the restructuring plan submitted by Cryo-Cell International and given the company until September 9, 2027 to regain compliance with listing requirements. Cryo-Cell reported a stockholders' equity deficit as of November 30, 2025, net losses in two of the last three fiscal years, a current ratio of 0.62 and undiluted earnings per share of -$0.33 (last 12 months). The common shares remain provisionally listed and tradable; failure to comply or lack of progress could trigger delisting proceedings. Analysts see a possible EPS of $0.11 for 2026. » Więcej na de.investing.com

Cryo-Cell received a written notice from the NYSE American after reporting a shareholders’ deficit as of November 30, 2025, and recording net losses in two of the last three fiscal years. The company reported negative earnings per share of $0.30 and a current ratio of 0.59, indicating liquidity pressure. Common shares continue to trade under the ticker CCEL for now, while Cryo-Cell intends to submit a plan to regain compliance; if accepted, the exchange typically allows up to 18 months to cure the deficiencies. Analysts see a possible return to profitability with expected EPS of $0.08 for the current year, but restoration of the listing requirements is not guaranteed and delisting remains possible. » Więcej na de.investing.com

Cryo-Cell International agreed with Susser Bank to a fifth amendment to its credit agreement: the revolving credit facility was extended to October 18, 2027, the term loan to July 29, 2032, and the revolving credit line was reduced from USD 10 million to USD 8 million. New interest terms include base rates of 4.25% (term loan) and 3.75% (revolving) plus monthly SOFR rates; a commitment fee of 0.25% applies. The company has suspended the quarterly cash dividend for Q3 2025 and cites lower-than-expected profitability; future distributions will depend on financial condition, capital needs and strategy. » Więcej na de.investing.com